Assignee
SYNTHORX INC
US·13 granted patents·23 pending applications·63 citations·filing 2016–2025
Top patents by PatentIndex Score
36 records- 0196US11077195B2IL-2 conjugates and methods of use thereofSYNTHORX INC·Filed 2020·Granted Aug 3, 2021·11 cites·33 claims
- 0296US10610571B2Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2019·Granted Apr 7, 2020·30 cites·30 claims
- 0395US11701407B2Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2020·Granted Jul 18, 2023·7 cites·28 claims
- 0495US11622993B2Cytokine conjugates for the treatment of autoimmune diseasesSYNTHORX INC·Filed 2018·Granted Apr 11, 2023·9 cites·19 claims
- 0593US12377131B2Cytokine conjugates for the treatment of autoimmune diseasesSYNTHORX INC·Filed 2023·Granted Aug 5, 2025·1 cites·23 claims
- 0692US11834689B2Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2021·Granted Dec 5, 2023·4 cites·25 claims
- 0787US12521437B2IL-2 conjugates and methods of use thereofSYNTHORX INC·Filed 2021·Granted Jan 13, 2026·1 cites·33 claims
- 0885US12318431B2Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2023·Granted Jun 3, 2025·0 cites·21 claims
- 0985US2025325633A1Cytokine conjugates for the treatment of autoimmune diseasesSYNTHORX INC·Filed 2025·Application pending·0 cites
- 1083US12319944B2Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2023·Granted Jun 3, 2025·0 cites·28 claims
- 1183US2025084410A1Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2024·Application pending·0 cites
- 1278US2025270535A1Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2025·Application pending·0 cites
- 1375US2025154218A1IL-2 Conjugates and Methods of Use to Treat Autoimmune DiseasesSYNTHORX INC·Filed 2024·Application pending·0 cites
- 1474US2024383957A1IL-15 Conjugates and Uses ThereofSYNTHORX INC·Filed 2024·Application pending·0 cites
- 1574US2025325632A1Cytokine conjugates for the treatment of proliferative and infectious diseasesSYNTHORX INC·Filed 2025·Application pending·0 cites
- 1673US2024287151A1IL-15 Conjugates and Uses ThereofSYNTHORX INC·Filed 2024·Application pending·0 cites
- 1769US2024245792A1Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 1869US2019376054A1Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2019·Application pending·0 cites
- 1969US2024226309A1Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 2068US2020024597A1Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2019·Application pending·0 cites
- 2166US11919934B2IL-15 conjugates and uses thereofSYNTHORX INC·Filed 2020·Granted Mar 5, 2024·0 cites·21 claims
- 2265US2020131555A1Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2018·Application pending·0 cites
- 2364US2023416327A1Immuno oncology therapies with il-2 conjugatesSYNTHORX INC·Filed 2023·Application pending·0 cites
- 2463US2023277627A1Immuno oncology combination therapy with il-2 conjugates and pembrolizumabSYNTHORX INC·Filed 2023·Application pending·0 cites
- 2562US12344648B2IL-15 conjugates and uses thereofSYNTHORX INC·Filed 2020·Granted Jul 1, 2025·0 cites·33 claims
- 2662US12234271B2Il-2 conjugates and methods of use to treat autoimmune diseasesSYNTHORX INC·Filed 2020·Granted Feb 25, 2025·0 cites·57 claims
- 2762US2020246467A1Il-2 conjugates and methods of use thereofSYNTHORX INC·Filed 2020·Application pending·0 cites
- 2859US2022273767A1Interleukin 10 Conjugates and Uses ThereofSYNTHORX INC·Filed 2022·Application pending·0 cites
- 2959US2023381335A1Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereofSYNTHORX INC·Filed 2023·Application pending·0 cites
- 3058US2023392140A1Reverse transcription of polynucleotides comprising unnatural nucleotidesSYNTHORX INC·Filed 2023·Application pending·0 cites
- 3158US2025302950A1Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumabSYNTHORX INC·Filed 2022·Application pending·0 cites
- 3257US12491254B2Interleukin 10 conjugates and uses thereofSYNTHORX INC·Filed 2021·Granted Dec 9, 2025·0 cites·18 claims
- 3355US2025075276A1Methods for selecting subjects and treating cancer with il-2 therapySYNTHORX INC·Filed 2023·Application pending·0 cites
- 3455US2017369871A1Incorporation of unnatural nucleotides and methods thereofSYNTHORX INC·Filed 2016·Application pending·0 cites
- 3550US2021046160A1Immuno Oncology Combination Therapies With IL-2 ConjugatesSYNTHORX INC·Filed 2020·Application pending·0 cites
- 3648US2022016252A1Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodiesSYNTHORX INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SYNTHORX INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →